Open access · CC-BY
via OpenAlex
Weight Gain in Type 2 Diabetes Mellitus Patients Receiving Sulfonylurea Medications at a Tertiary Hospital in Surabaya, Indonesia
Ghagat Dresta Putra Respati, Jongky Hendro Prajitno, Rosy Setiawati, Rio Wironegoro
Current Internal Medicine Research and Practice Surabaya Journal · 2025
Abstract
Introduction: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. The prevalence of diabetes in Indonesia is 1.5%, although East Java recorded a 2.1% rate in 2013. T2DM medications, such as sulfonylureas, may lead to hypoglycemia and weight gain. This study aimed to investigate the weight gain effects of sulfonylureas in T2DM patients at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Methods: This retrospective cross-sectional study used retrograde anamnesis on 41 T2DM patients receiving sulfonylurea medications for the preceding six months. The data were collected from medical records and interviews with the T2DM patients who received treatment at the Internal Medicine Clinic of Dr. Soetomo General Academic Hospital from January to June 2022. Results: Most patients were 46–65 years old (73.2%), female (51.2%), and had been diabetic for over 15 years (48.8%). The predominant medications administered to the patients were glimepiride (41.4%) and a combination of glibenclamide 5 mg, metformin 500 mg, and acarbose 100 mg (19.5%). Almost all patients took their medications in the morning before meals (92.6%). The average weight gain was 4.6 kg, with the glibenclamide and metformin combination resulting in a 17% incidence. Conclusion: T2DM patients who use sulfonylureas generally gain weight and exhibit specific traits, including being middle-aged, female, and diabetic for multiple years. The most commonly used sulfonylureas are glimepiride for monotherapy and glibenclamide for combination therapy with metformin and acarbose. Future research is required to understand weight gain in T2DM patients treated with sulfonylureas more comprehensively. Highlights: This study investigated weight changes in type 2 diabetes mellitus (T2DM) patients receiving sulfonylureas, with a special focus on the emergence of weight gain as a new problem in T2DM management. The importance of this study pertains to its findings regarding weight gain in T2DM patients treated with sulfonylureas, offering additional data that aids in preventing adverse effects of the medications.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.20473/cimrj.v6i1.52126
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Respati, G.D.P., Prajitno, J.H., Setiawati, R., & Wironegoro, R. (2025). Weight Gain in Type 2 Diabetes Mellitus Patients Receiving Sulfonylurea Medications at a Tertiary Hospital in Surabaya, Indonesia. <em>Current Internal Medicine Research and Practice Surabaya Journal</em>. https://doi.org/10.20473/cimrj.v6i1.52126
Vancouver
Respati GDP, Prajitno JH, Setiawati R, Wironegoro R. Weight Gain in Type 2 Diabetes Mellitus Patients Receiving Sulfonylurea Medications at a Tertiary Hospital in Surabaya, Indonesia. Current Internal Medicine Research and Practice Surabaya Journal. 2025. doi:10.20473/cimrj.v6i1.52126.
BibTeX
@article{ghagat2025Weight,
title = {Weight Gain in Type 2 Diabetes Mellitus Patients Receiving Sulfonylurea Medications at a Tertiary Hospital in Surabaya, Indonesia},
author = {Ghagat Dresta Putra Respati and Jongky Hendro Prajitno and Rosy Setiawati and Rio Wironegoro},
journal = {Current Internal Medicine Research and Practice Surabaya Journal},
year = {2025},
doi = {10.20473/cimrj.v6i1.52126},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Brain and Behavior 2020
Open access · CC-BY
Neurodegeneration in type 2 diabetes: Alzheimer's as a case study
2022
Open access · CC-BY
Clinical and Metabolic Characterization of Adults with Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort
2022
Open access · CC-BY
Clinical and Metabolic Characterization of Adults with Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort
2022
Open access · CC-BY
Clinical and Metabolic Characterization of Adults with Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort
Metabolic Syndrome and Related Disorders 2007
Citation only
Metabolic Syndrome in Type 2 Diabetes Mellitus in Isfahan, Iran: Prevalence and Risk Factors
Research Square 2024
Preprint · CC-BY